rapid expansion of domestic biotech infrastructure, and increasing international collaborations. In recent developments, ...

"As our second product approved by Health Canada, mRESVIA underscores our commitment to leveraging mRNA technology to protect ...

The global mRNA synthesis and manufacturing market is projected to grow from USD 2,231.4 million in 2024 to USD 2,958.3 ...

The Nucleic Acid Therapeutics Initiative (NATi), a national platform hosted by the Agency for Science, Technology and Research (A*STAR), officially launched the non-GMP NATi mRNA BioFoundry today.

Vernal Biosciences Appoints Jim Petrilla as CEO and Board Director. New Leadership Reflects Commitment to Advancing mRNA Technologies and Operational Excellence, Helping Drug Developers Deliver ...

Production tips from Crystal Bio, TriLink Biotechnologies, Ginkgo Bioworks, Quantoom Biosciences, and Parexel.

Arcturus Therapeutics ( (ARCT) ) has released its Q3 earnings. Here is a breakdown of the information Arcturus Therapeutics presented to its ...

We recently published a list of the 10 Worst Performing Stocks in S&P 500 in 2024. In this article, we are going to take a ...

Health Canada approves Moderna’s RSV vaccine, mRESVIA for adults aged 60 years and older: Cambridge, Massachusetts Monday, November 11, 2024, 12:00 Hrs [IST] Moderna, Inc., a le ...

He will lead Vernal in its mission of advancing mRNA technology to reshape modern healthcare. "We are thrilled to welcome Jim to Vernal Biosciences," says Cobaugh. "His proven ability to deliver ...